Ocumension Therapeutics disclosed that Chief Financial Officer, Joint Company Secretary and Authorized Representative Tim Ruan will step down on 30 June 2026 for personal reasons. Ruan confirmed no disagreements with the board and no matters requiring shareholder attention.

The finance team, led by the company’s finance director, will assume responsibility for financial management. The board stated that the leadership change is not expected to materially affect the Group’s financial operations.

Effective the same date, current Joint Company Secretary Tingchan Chen will become the sole Company Secretary and an Authorized Representative. Chen meets the professional qualifications under Hong Kong Listing Rules 3.28 and 8.17, has corporate governance experience, and has been an associate member of The Hong Kong Chartered Governance Institute since July 2023.

The board expressed gratitude to Ruan for his service and welcomed Chen to her expanded role. Ocumension affirmed continued compliance with Listing Rules 3.05, 3.28 and 8.17 following these changes.